SCHEMBL3978041

SCHEMBL3978041

[NH]C(=O)c1cc(-c2ccc(F)c(Cl)c2)ccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.50
ERCC4 Q92889 1/20 0.50
HSD17B1 P14061 4/20 0.49
HSD17B2 P37059 4/20 0.49
PIK3CA P42336 3/20 0.44
CASP1 P29466 1/20 0.43
RPA1 P27694 1/20 0.43
ACMSD Q8TDX5 3/20 0.42
KMO O15229 2/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
DHFR P00374 2/20 0.41
HNF4A P41235 1/20 0.41
MCL1 Q07820 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3979148 0.85 ACMSD (0.59) ERCC1ERCC4HSD17B1HSD17B2RPA1
SCHEMBL3978045 0.84 CASP1 (0.57) ERCC1ERCC4HSD17B1HSD17B2PIK3CA
SCHEMBL3979604 0.80 CA12 (0.53) ERCC1ERCC4HSD17B1HSD17B2PIK3CA
SCHEMBL6153483 0.75 CA1 (0.67) MEN1USP2CA1CA2LMNA
SCHEMBL11693280 0.74 AKR1C2 (0.66) ERCC1ERCC4CASP1RPA1KMO
SCHEMBL5927653 0.72 KIF11 (0.48) PIK3CAACMSDDHFRHNF4AMCL1
SCHEMBL5926859 0.72 ALOX5 (0.42) ERCC1ERCC4HSD17B1HSD17B2MEN1
SCHEMBL8779130 0.71 KMO (0.55) ERCC1ERCC4HSD17B1HSD17B2CASP1
SCHEMBL16608990 0.71 RPA1 (0.58) ERCC1ERCC4PIK3CACASP1RPA1
SCHEMBL5926863 0.71 CDK1 (0.44) ERCC1ERCC4HSD17B1HSD17B2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501538-B2 Aryl and heteroaryl compounds, compositions and methods of use TRANSTECH PHARMA, INC. (US) 2009-03-10 US claimed
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use VTVX HOLDINGS I LLC 2005-03-03 US claimed
WO-2005014532-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO claimed
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use VTVX HOLDINGS I LLC 2005-03-03 US disclosed
WO-2005014532-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049310-A1 Aryl and heteroaryl compounds, compositions and methods of use EPOR, HBG2, CYP2F1 ERCC1 3366/4885ERCC4 1876/4885HSD17B1 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.